title: The positive clinical therapeutically effects of Escin on advanced thyroid cancer.
abstract: The incidences of thyroid cancer keep rising worldwide over the past few decades. Although most thyroid cancers are indolent and highly curable, the treatment for advanced thyroid cancer remains challengeable in clinical practice. We performed two separate cohorts to evaluate the safety and efficiency of Escin in patients with advanced thyroid cancer . In cohort 1, 120 patients were divided into four groups equally and were administrated with placebo or different dosages of Escin. The pharmacokinetics of Escin and the side effects were evaluated. In cohort 2, 120 patients were treated with Escin. Several biomarkers related to the progression of thyroid cancer were evaluated. Kaplan-Meier (KM) analyses were performed to evaluate progression-free survival (PFS) and overall survival (OS). The serum Escin concentrations were stable during the treatment. Escin (0.6 mg/kg/day for 9 days, intravenous injection) was tolerable for patients with thyroid cancer . Escin significantly reduced the serum levels of TSH, TgAb, Tg, and calcitonin and prolonged the PFS and OS for patients with advanced thyroid cancer. This study showed Escin is efficient and well tolerated in patients with advanced thyroid cancer. Future studies are needed to investigate the mechanism of Escin on thyroid cancer and the proper dosage of Escin clinically.
authors.affiliation: Department of Otolaryngology, The First Hospital of Anhui Medical University, Hefei, 230031, China.|Department of Otolaryngology, The Second Hospital of Anhui Medical University, Hefei, 230601, China.
authors.forename: Jin-Yu
authors.initials: JY
authors.lastname: Mei
authors.affiliation: Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, China.
authors.forename: Ming-Jun
authors.initials: MJ
authors.lastname: Zhang
authors.affiliation: Department of Pharmacy, The Second Hospital of Anhui Medical University, Hefei, 230601, China.
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Wang
authors.affiliation: Department of Otolaryngology, The First Hospital of Anhui Medical University, Hefei, 230031, China.
authors.forename: Ye-Hai
authors.identifier: http://orcid.org/0000-0002-3642-840X
authors.initials: YH
authors.lastname: Liu
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002116:Calcitonin / Q000097:blood; D004928:Escin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy*; D013972:Thyrotropin / Q000097:blood; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D004928:Escin; D013972:Thyrotropin; D002116:Calcitonin; D013954:Thyroglobulin
keywords: Advanced thyroid cancer; Escin; pharmacokinetics; side effects